Astria Therapeutics
ATXS
ATXS was delisted on the 22nd of January, 2026.
33 hedge funds and large institutions have $41.7M invested in Astria Therapeutics in 2022 Q1 according to their latest regulatory filings, with 6 funds opening new positions, 7 increasing their positions, 8 reducing their positions, and 6 closing their positions.
144% more call options, than puts
Call options by funds: $3.54M | Put options by funds: $1.45M
27% more capital invested
Capital invested by funds: $32.8M → $41.7M (+$8.83M)
0.86% more ownership
Funds ownership: 46.84% → 47.7% (+0.86%)
0% more funds holding
Funds holding: 33 → 33 (0)
0% more first-time investments, than exits
New positions opened: 6 | Existing positions closed: 6
13% less repeat investments, than reductions
Existing positions increased: 7 | Existing positions reduced: 8
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
+$2.11M |
| 2 |
Citadel Advisors
Miami,
Florida
|
+$127K |
| 3 |
BCM
Bridgeway Capital Management
Houston,
Texas
|
+$115K |
| 4 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$110K |
| 5 |
Geode Capital Management
Boston,
Massachusetts
|
+$78K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CAM
Cormorant Asset Management
Boston,
Massachusetts
|
-$1.51M |
| 2 |
Renaissance Technologies
New York
|
-$185K |
| 3 |
D.E. Shaw & Co
New York
|
-$79.8K |
| 4 |
Wolverine Trading
Chicago,
Illinois
|
-$76.4K |
| 5 |
OWP
Old Well Partners
Charlotte,
North Carolina
|
-$65K |
ATXS Hedge Fund Activity: Q1 2022 in Review
33 of the 6,360 institutional investors tracked by Wall St. Rank reported a position in Astria Therapeutics (ATXS) for Q1 2022, worth a combined $41.7M — up 27% from $32.8M a quarter earlier.
Fund positioning in ATXS was balanced in Q1 2022: 6 funds opened new positions, 6 closed out, 7 added to existing stakes and 8 trimmed.
The largest buyer was Fidelity Investments, opening a new position worth an estimated $2.11M. The largest seller was Cormorant Asset Management, cutting an estimated $1.51M.
- 33 institutional investors held Astria Therapeutics (ATXS) as of Q1 2022, unchanged from Q4 2021.
- Funds reported $41.7M of Astria Therapeutics stock for Q1 2022, up 27% quarter-over-quarter.
- 6 funds opened new Astria Therapeutics positions in Q1 2022 and 6 closed out, a net change of 0 holders.
- The largest Astria Therapeutics buyer in Q1 2022 was Fidelity Investments, an estimated $2.11M added.
- The largest Astria Therapeutics seller in Q1 2022 was Cormorant Asset Management, an estimated $1.51M sold.
Based on aggregated 13F filings for Q1 2022.